### Second Edition

## Pharmaceutical Formulation Development of Peptides and Proteins

Edited by Lars Hovgaard Sven Frokjaer Marco van de Weert





CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW. Suite 300 Boca Raton, FL 33487-2742

© 2013 by Taylor & Francis Group, LLC CRC Press is an Imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Printed in the United States of America on acid-free paper Version Date: 20121003

International Standard Book Number: 978-1-4398-5388-7 (Hardback)

This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and spologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, mitorofilaning, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danwers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

#### Library of Congress Cataloging-in-Publication Data

Pharmaceutical formulation development of peptides and proteins / editors, Lars Hovgaard, Sven Frok)aer. Marco van de Weert. — 2nd ed. p.: cm. Includes bibliographical references and index. Includes bibliographical references and index. ISBN 978-1-4398-5388-7 (hardcover : alk, paper)

1. Hovgaard, Lars, 1962-11. Frok/ser, Sven. 1947-111. Weert, Marco van de, 1973-(DNLM: 1. Peptide Biosynthesis. 2. Chemistry, Pharmaceutical--methods. 3. Pretein Biosynthesis. QU 68]

615.1'9-dc23

2012030490

Visit the Taylor & Francis Web site at http://www.taylorandfrancis.com and the CRC Press Web site at http://www.crcpress.com




## Contents

	ix
Chapter 1	Peptide Synthesis
	Knud J. Jensen
Chapter 2	Protein Expression
	Nanni Din
2000	Protein Purification
	Lars Hovgaard, Lars Skriver, and Sven Frokjaer
Chapter 4	Characterization of Therapeutic Peptides and Proteins
	Marco van de Weert and Tudor Arvinte
Chapter 5	Chemical Pathways of Peptide and Protein Degradation
	Teruna J. Siahaan and Christian Schöneich
Chapter 6	Physical Instability of Peptides and Proteins
	Marco van de Weert and Theodore W. Randolph
Chapter 7	Peptide and Protein Derivatives
	Kristian Strømgaard and Thomas Høeg-Jensen
Chapter 8	Peptides and Proteins as Parenteral Solutions
	Michael J. Akers and Michael R. DeFelippis
Chapter 9	Peptides and Proteins as Parenteral Suspensions: An Overview of Design, Development, and Manufacturing Considerations 193
	Michael R. DeFelippis and Michael J. Akers



vi	Contents
Chapter 10	Rational Design of Solid Protein Formulations
	Bingquan (Smart) Wang and Michael J. Pikal
Chapter 11	Peptide and Protein Drug Delivery Systems for Nonparenteral Routes of Administration 269
	Ulrik Lytt Rahbek, František Hubálek, and Simon Bjerregaard
Chapter 12	Immunogenicity of Therapeutic Proteins
	Grzegørz Kijanka. Wim Jiskoot, Melody Suuerborn, Huub Schellekens, and Vera Brinks
Chapter 13	Biosimulation of Peptides and Proteins
	Tue Søeborg, Christian Hove Rasmussen, Erik Mosekilde, and Morten Colding-Jørgensen
Chapter 14	Registration of Peptides and Proteins
	Niamh Kinsella
Index	363



## 6 Physical Instability of Peptides and Proteins

Marco van de Weert and Theodore W. Randolph

### CONTENTS

6.1	Introduction		
6.2	Protei	n Structure	
	6.2.1	Peptides, Polypeptides, and Proteins	
	6.2.2	Protein Structure: Primary, Secondary, Tertiary, and	
		Quaternary Structure	
6.3	Protei	n Folding: Why Do Proteins Fold? 109	
	6.3.1	Role of Water and Stabilizing Interactions	
	6.3.2	The Energy Landscape of a Protein Molecule 111	
6.4	Protei	n Physical Degradation	
	6.4.1	Protein Unfolding114	
	6.4.2	Adsorption 117	
	6.4.3	Protein Aggregation	
		6.4.3.1 Aggregation Mechanisms and Kinetics 119	
		6.4.3.2 Fibrillation: A Special Case of Protein Aggregation 120	
	6.4.4	Protein Precipitation	
6.5	Stabilization Strategies		
6.6	Concluding Remarks		
Ref	erences.	. 126	

### 6.1 INTRODUCTION

The biological function of peptides and proteins is highly dependent on their three-dimensional structure. Changes in that structure, which may arise due to chemical or physical processes, may alter or abolish that function, or even result in toxicity. Thus, it is of importance that a pharmaceutical formulation of therapeutic peptides and proteins retains the normal (native) structure of those peptides or proteins, or that any changes are fully reversible upon administration to the patient.

A major difference between proteins and low molecular weight drugs is the com-

A major difference between proteins and low molecular weight drugs is the complexity of the three-dimensional structure and concomitant sensitivity toward external stress factors. The three-dimensional structure of proteins is mostly held together by noncovalent interactions, such as hydrogen bonds, salt bridges, and van der Waals forces. Any stress factor may alter these noncovalent interactions, possibly leading to new intra- or intermolecular interactions which may not be reversible upon removing the stress factor.





# DOCKET

## Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

